Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
BACKGROUND
Premature discontinuation and other forms of noncompliance with treatment assignment can complicate causal inference of treatment effects in randomized trials. The intent-to-treat analysis gives unbiased estimates for causal effects of treatment assignment on outcome, but may understate potential benefit or harm of actual treatment. The corresponding upper confidence limit can also be underestimated.


OBJECTIVE
To compare estimates of the hazard ratio and upper bound of the two-sided 95% confidence interval from causal inference methods that account for noncompliance with those from the intent-to-treat analysis.


METHODS
We used simulations with parameters chosen to reflect cardiovascular safety trials of diabetes drugs, with a focus on upper bound estimates relative to 1.3, based on regulatory guidelines. A total of 1000 simulations were run under each parameter combination for a hypothetical trial of 10,000 total subjects randomly assigned to active treatment or control at 1:1 ratio. Noncompliance was considered in the form of treatment discontinuation and cross-over at specified proportions, with an assumed true hazard ratio of 0.9, 1, and 1.3, respectively. Various levels of risk associated with being a non-complier (independent of treatment status) were evaluated. Hazard ratio and upper bound estimates from causal survival analysis and intent-to-treat were obtained from each simulation and summarized under each parameter setting.


RESULTS
Causal analysis estimated the true hazard ratio with little bias in almost all settings examined. Intent-to-treat was unbiased only when the true hazard ratio = 1; otherwise it underestimated both benefit and harm. When upper bound estimates from intent-to-treat were ≥1.3, corresponding estimates from causal analysis were also ≥1.3 in almost 100% of the simulations, regardless of the true hazard ratio. When upper bound estimates from intent-to-treat were <1.3 and the true hazard ratio = 1, corresponding upper bound estimates from causal analysis were ≥1.3 in up to 66% of the simulations under some settings.


CONCLUSIONS
Simulations cannot cover all scenarios for noncompliance in real randomized trials.


CONCLUSIONS
Causal survival analysis was superior to intent-to-treat in estimating the true hazard ratio with respect to bias in the presence of noncompliance. However, its large variance should be considered for safety upper bound exclusion especially when the true hazard ratio = 1. Our simulations provided a broad reference for practical considerations of bias-variance trade-off in dealing with noncompliance in cardiovascular safety trials of diabetes drugs. Further research is warranted for the development and application of causal inference methods in the evaluation of safety upper bounds.
Janssen Research & Development, LLC, Titusville, NJ, USA Ywang28@its.jnj.com.
Yiting
Y
Wang
Johnson & Johnson, Titusville, NJ, USA.
Jesse A
JA
Berlin
Janssen Research & Development, LLC, Raritan, NJ, USA.
José
J
Pinheiro
Janssen Research & Development, LLC, Titusville, NJ, USA.
Marsha A
MA
Wilcox
D015982:Bias; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000628:therapy; D015984:Causality; D003198:Computer Simulation; D003627:Data Interpretation, Statistical; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D010349:Patient Compliance / Q000706:statistics & numerical data*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design
Noncompliance; causal survival analysis; major adverse cardiovascular events; safety upper bound